Having the hostile M&A controversy, Ildong Pharmaceutical will pay KRW 1.47 billion cash dividends to Green Cross

While a part of the pharmaceutical industry expects that Green Cross will try a hostile M&A on Ildong Pharmaceutical, Green Cross will receive KRW 1.471 billion cash dividends through distribution of the Ildong Pharmaceutical’s account settlement.

Moreover, the holding company of Hanmi Pharmaceutical, Hanmi Science, will receive approximately KRW 760 million cash dividends through distribution...